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Stent thrombosis is a major complication that occurs after the placement of stents 
in the coronary artery through balloon angioplasty, associated with severe medical 
conditions with a high risk of mortality. The common treatment for stent thrombosis is to 
provide patients with anticoagulant and antiplatelet therapy through the bloodstream, 
which has the adverse effect of increased risk of bleeding disorders. This study uses 
numerical modeling to compare two delivery methods of anticoagulant to the arterial wall 
to reduce thrombus formation: through the flow and via a drug-eluting stent. A two-
dimensional thrombosis model is developed that couples an incompressible flow solver 
with a convection-diffusion-reaction equation model of the coagulation cascade and 
platelet activation and aggregation. The results find that the drug-eluting stent delivery of 
anticoagulant is more effective in reducing platelet activation and clotting, while also 
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Blood flow in the human body is regulated by a variety of physical and chemical 
processes. In the event of injury to vascular tissue in the body, there is a complex set of 
responses known as hemostasis that is used to maintain the integrity of the tissue wall and 
blood flows. The first response to such tissue damage is to plug the injured area with an 
aggregated mass of platelets. This process of blood clotting is known as thrombus 
formation. 
There exist a multitude of different biochemical, biophysical, and biomechanical 
mechanisms that govern platelet activity and thrombus formation. When working 
properly the set of processes produces a blood clot localized at the site of the injury, 
which acts to stop hemorrhage as the blood vessel heals. These processes are initiated by 
certain chemical agents released from the injured tissue wall, and also by the mechanical 
conditions to which the platelets are subjected. 
However, thrombus formation can sometimes occur in arteries and veins when 
pathologic processes interfere with the natural mechanisms of hemostasis, creating 
unnecessary clots that can obstruct normal blood flow. This event, known as thrombosis, 
is the cause of cardiovascular conditions such as myocardial infarction, stroke, and 




Timely and accurate detection of thrombosis is vital for effective treatment, and 
the development of a patient-specific thrombus formation model would be a powerful 
tool in the prediction of thrombosis in blood flows. This work in this essay is purposed 
towards developing and applying such a computational model to study the effect of anti-
thrombotic therapy in patients with stents.  
1.1 Overview of Thrombosis 
1.1.1 Platelet Characteristics 
 
Figure 1: From left to right, scanning electron microscope images of resting, 
partially activated, and fully activated human platelets. [21] 
Platelets, or thrombocytes, are non-nucleated cells that are created by bone 
marrow megakaryocytes and released into the bloodstream, where they circulate freely. 
Typical platelet count is about 150-350 × 109 L-1, which forms about three percent of all 
particulate matter in human blood. [1] The lifespan of a platelet is 8-10 days, and in total 
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the human body contains about one trillion platelets, of which 1 × 1011 are produced 
daily. [19] [21] In their resting form they are smooth and discoid in shape with a cell 
diameter of 1-2 µm and a volume of approximately 6 µm3. [1] [19] 
Platelets are used to block hemorrhage after vascular tissue injury, and this is 
done through the process of activation. The outermost glycoprotein layer of the platelets, 
or glycocalyx, contains receptors for activating factors (e.g. collagen-bound von 
Willebrand factor, thrombin, or ADP) as well as for inhibitors, adhesive agents, and 
aggregating agents. [1] [13] When the platelet is activated, it changes shape from a 
flattened discoid into a spheroid, and extends many pseudopods to interact with other 
activated platelets. [19] Figure 1 illustrates this shape change between resting and 
activated platelets. 
 












Figure 2: Thrombus formation as a typical response to vascular tissue injury. [13] 
To produce a thrombus as a response to damaged vascular tissue, typically three 
separate processes must occur. First, platelets must be activated through chemical 
pathways. These activated platelets must then bind locally to the endothelial wall of the 
injured vessel. Simultaneously, they must also attach to other activated platelets to create 
an aggregate that effectively plugs the damaged area and prevents hemorrhage as it heals. 
Figure 2 depicts characteristic thrombus development following this process. 
 
Platelet Activation 
The plasma membrane of the platelet contains receptors for several different 
biochemical factors, each with their own unique signaling pathways that are effected by 
enzymatic reactions. As a result, there exist various chemicals and signaling factors that 
can activate a platelet. Activation can be stimulated by any of the following 
biomolecules: von Willebrand factor (vWF), collagen, thrombin, thromboxane, serotonin, 
adenosine diphosphate (ADP), or epinephrine binding to their own specific receptors on 
the platelet membrane. [13] [21] 
There are two distinct pathways that are naturally used by the body to trigger 
activation. Platelets are activated in response to blood vessel tissue injury, so the first 
mechanism is by the exposure of platelets to subendothelial collagen in the tissue. 
Collagen is a matrix protein found in most body tissues, with its primary role being 
structural. Collagen itself can interact with platelet glycoprotein VI on the membrane, and 
collagen-bound von Willebrand factor also can bind with platelet glycoprotein Ib-V-IX to 
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initiate activation. [13] Eventually this signaling pathway activates platelet integrin and 
leads to adhesion to the vessel wall. [14] 
The second pathway is separately initiated by an agent known as tissue factor 
(TF). Tissue factor normally resides in the endothelium and is only exposed to the 
bloodstream when the vessel wall is ruptured, exposing the subendothelial tissue. Upon 
contact with blood, tissue factor binds with factor VII that flows through the bloodstream 
to form the complex TF:VIIa. [4] [13] [14] This sets into motion the coagulation cascade 
(CC), a series of enzyme reactions in the bloodstream that are ultimately responsible for 
the production of thrombin. Through a platelet surface reaction, thrombin cleaves a 
protease-activated receptor to activate the platelet. [13] 
After the completion of either pathway, the activated platelet itself becomes a 
source for chemical agonists. Active platelets release thromboxane A2, ADP, and 
serotonin into the nearby blood, all of which are potential activators for additional 
platelets through surface membrane chemical reactions. [8] [13] 
 
Platelet Adhesion 
Activated platelets bind to the injured cell wall through the process of adhesion. 
Healthy endothelial cells produce the glycoprotein von Willebrand factor and secrete it 
into the subendothelial matrix, where some of it also binds to the collagen in the matrix. 
[19] If the vessel wall is ruptured then von Willebrand factor and collagen are exposed to 
activated platelets in the bloodstream. Von Willebrand factor binds to the glycoprotein 
(GP) IIb/IIIa and GP Ib-V-IX complexes on the membrane of the extended pseudopods 
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of the activated platelet, while collagen binds with GP VI. The collagen-GP VI link is 
required for binding the platelet to the exposed subendothelium. [13] 
Since adhesion is a process that connects free flowing platelets from the 
bloodstream to the relatively stationary wall, the links must be able to withstand the 
forces induced by the flow of blood. The importance of the different links is determined 
by the local wall shear rates and stresses. Higher shear rates limit the time of contact 
between platelets and the vessel wall and thus the amount of wall binding is reduced. In 
the event of high shear rates, only the vWF link with GP Ib-V-IX occurs quickly enough 
to effectively snag platelets from the blood. However for lower shear rates the process 
can occur even without the presence of vWF. Relatedly, higher shear stresses reduce the 
lifetime of established platelet links and make it easier for adhered platelets to detach 
from the wall. [13] [19] [33] 
 
Platelet Aggregation 
The platelets bound to the subendothelial wall also attach themselves to other 
activated platelets, leading to the formation and growth of a clot. This process is known 
as aggregation. It is related to adhesion in that many of the same adhesive ligand and 
receptor pairs are used, only they attach to the membranes of wall-bound platelets instead 
of the matrix and tissues of the vascular wall. [32] Specifically, the complexes GpIb and 
GpIIb-IIIa are used as receptors for von Willebrand factor and fibrinogen/fibrin protein 
links between platelets. [1] [19] As with adhesion, platelet aggregation is adversely 
impacted by high shear stresses. [1] 
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Concurrently to the formation of platelet-platelet links, a fibrin matrix is 
assembled at the location of the clot. Fibrinogen is converted to fibrin monomers called 
protofibrils through the action of thrombin from the coagulation cascade. [1] The 
protofibrils branch and form a three-dimensional matrix around and through the clot. 
They are cross-linked together via Factor XIII, a blood-borne transglutaminase that is 
activated by thrombin. As platelets attach to this growing fibrin matrix the clot grows in 
size. The fibrin matrix offers the bound platelets protection from both mechanical stresses 
and chemical breakdown, and the resulting platelet-fibrin structure represents the end 
product of thrombus formation. [5] [19] 
Clot dissolution after the tissue has healed is characterized by the process of 
fibrinolysis. Fibrinolysis is triggered by the release of tissue PLS activator (tPA) and 
urokinase-like PLS activator (uPA) from endothelial cells through the action of thrombin 
and fibrin. Since these activators are secreted from healthy endothelial cells, this process 
occurs after the vascular tissue has healed and an intact endothelium has formed over the 
previously injured area. These chemicals transform PLS into the enzyme plasmin, which 
acts to break up the fibrin matrix. After this, various inhibitory factors act on the 





1.1.3 The Coagulation Cascade and Clot Formation 
 
Figure 3: A schematic of the coagulation cascade including species and reactions. 
The dashed magenta arrows represent activation processes, blue arrows represent 
chemical transport, green segments represent surface binding/unbinding, solid black lines 
represent forward enzyme action, dashed black lines show enzyme feedback, and red 
disks represent chemical inhibitors. [22] 
 
The coagulation cascade refers to a series of reactions with the net result of 
producing thrombin and ultimately fibrin. The term cascade refers to the amplification 
property of the reactions: small amounts of initial chemicals are used activate much 
larger quantities of later enzymes and products. Injury to the vessel wall initiates this 
process, which supplies the additional chemicals that are needed to take free, mobile 
platelets from the blood, activate them, and form a clot local to the site of the injury. The 
various chemical reactions take place on the subendothelium and platelet surfaces as well 
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as in the free stream of the blood. [5] The coagulation cascade contains a main extrinsic 
pathway, as well as an intrinsic pathway characterized by contact activation. [1] [4] [12] 
Figure 3 shows the many different reactions and agents of the coagulation cascade. 
For the extrinsic pathway, coagulation is initiated by the release of tissue factor, a 
membrane protein normally found in different cellular compartments. When not used in 
the coagulation cascade it can also play a role in cellular signaling events for 
angiogenesis, tumor progression, metastasis, and yolk-sac vasculature maintenance. 
While latent tissue factor does exist in the bloodstream, coagulation is started when the 
active form is released through injury to the endothelium and reacts with factor VIIa in 
the blood. [13] Together they form factor TF:VIIa on the subendothelium as the first step 
in the coagulation cascade. After this, various proenzymes, or zymogens, are converted to 
their active enzyme states as the cascade progresses. [1] Tissue factor is also involved in 
positive feedback, as endothelium and activated platelets may also produce protein 
disulfide isomerase, which converts latent tissue factor to its active form. 
The common result of both the extrinsic and intrinsic coagulation pathways is the 
production of thrombin. As mentioned before, thrombin serves to activate platelets as 
well as form from fibrinogen the fibrin monomers that make up the blood clot. Thrombin 
also has a large role in feedback mechanisms for coagulation. It activates coagulation 
reaction factors XI, V, and VIII to effect the cascade, but it also catalyzes the formation 
of anticoagulant active protein C (APC). [1] [5] 
There exist three main chemical inhibitors for the coagulation cascade. The most 
important of these is Antithrombin III (ATIII). ATIII directly inhibits thrombin in a 1:1 
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ratio by binding to it, and it also binds to and deactivates factors Xa,  XIIa, IXa, and XIa. 
It also has an inhibitory effect on the subendothelium-bound TF:VIIa complex. [5] ATIII 
is found in the blood at much higher concentrations than any of the coagulation 
zymogens, and its activity is also significantly increased by sulfated heparin that is 
produced and released from endothelial cells. [1] Another chemical, tissue factor pathway 
inhibitor (TFPI), binds with factor Xa catalyzed by the TF:VIIa complex. TFPI is 
produced mainly in endothelial cells and its actions effectively disable the extrinsic 
pathway. APC is the third main inhibitor, and it deactivates factors Va and VIIa. [1] [4] 
[5] [12]  
Mechanical factors can also affect the coagulation reactions since these have an 
effect on platelet adhesion and aggregation. As various steps in the coagulation cascade 
take place on the surface of the platelets, the availability of binding sites is affected by 
the shear stresses in the blood. This is particularly true for the assembly of cascade 
intermediates tenase and prothrombinase. Experiments also suggest that fibrin formation 
is related to shear rates, and that fibrin can form even in areas with intact endothelium, 
most noticeably in recirculation zones. [1] 
 
1.2 Thrombosis in Selected Blood Flows 
When functioning properly, the aforementioned pathways help regulate 
concentrations of various chemicals as needed for hemostasis and allow vascular tissue to 
safely recover from injury. However, unwanted occurrences of thrombosis can produce 
11 
 
significant medical problems. A blood clot is capable of partially or even fully blocking a 
blood vessel. This leads to ischemia, or oxygen deprivation and tissue starvation 
downstream of the blockage. [5] Ischemia can result in tissue damage or death, which can 
be hazardous or even fatal for key organs of the body such as the heart or brain in 
myocardial infarction or stroke. [28] Also, if the clot is detached from its original location 
due to blood shear stresses, it can migrate through the bloodstream and affect faraway 
tissues as well. This is known as downstream embolization. [1] 
Thrombosis-related disorders that develop in the heart have a high risk associated 
with them. Atrial thrombosis can occur as a consequence of arrhythmia such as atrial 
fibrillation or atrial flutter. The impaired contraction of the atrium lowers the diastolic 
flow volume and speed of blood into the ventricle, leading to formation of a thrombus in 
the atrium. [1] Ventricular thrombosis is normally less likely than atrial thrombosis, but is 
often caused by local systolic dysfunction of the ventricle. For example, the incidence of 
left ventricular thrombosis (LVT) is high after myocardial infarction (MI) or severe 
apical wall abnormality. [2] [39] Systolic volume of the ventricle appears to play a role in 
the development of LVT. [30] Incidence of thrombosis on the heart valves themselves is 
naturally very rare, but thrombi do form more frequently on artificial mechanical valves. 
[1] 
Arterial and venous thrombosis occurs after the formation of an atherosclerotic 
plaque in a blood vessel, a slow process that can take many years. After its development, 
the plaque could go unstable and rupture, which triggers thrombosis. Thrombosis in the 
artery or vein causes stenosis, and a large enough clot leads to ischemia and its associated 
negative effects. [1] [5] Thrombosis also often occurs in aneurysms in vascular tissue, 
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where the extracellular matrix has been irreversibly remodeled causing a loss of structural 
integrity in the vessel wall. An Intra-Luminal Thrombus (ILT) tissue forms and causes 
localized hypoxia and wall thinning and weakening. This could eventually lead to a 
rupture, and for an aneurysm in the aorta, brain, or other important organs, the effect is 
likely to be fatal. [4] [29] Thrombosis can also occur in the veins of the lungs, which can 
migrate to the ventricle and become a pulmonary embolism. [21] It is also believed that 
inflammation and thrombosis are inherently linked; inflammation can initiate local 
thrombosis, and thrombosis can amplify inflammation. [8] [23] 
These thrombosis-related complications in the body are often linked to local 
blood flow properties. It is widely believed that local flow stagnation can induce 
thrombosis. Atrial thrombosis is caused by atrial arrhythmia, which affects the atrial 
blood flow considerably. [1] Abnormal flow as measured by Doppler echocardiography 
is considered one of the largest risk factors for the formation of LVT. [30] [39] Unstable 
atherosclerotic plaques in blood vessels often lead to regions of stenosis where flow 
instability and stagnation can be observed. [1] In aneurysms a strong correlation is 
observed between the locations of thrombi and low shear stresses and flow velocities. [4] 
[32] Pulmonary thrombus also occurs in the low flow venous circuit of the lungs. [21] It 
is clear that flow stagnation and abnormal flow are correlated to the location of thrombus 
formation. 
Various options are currently used to prevent and treat thrombosis-related 
complications. The most common treatment is anticoagulants such as heparin and 
warfarin that interfere with the coagulation cascade. Antiplatelet therapy, often used in 
arterial thrombosis, may also be used to prevent platelet aggregation. These can be given 
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through intravenous injections, subcutaneous injections, or oral methods. However, both 
of these treatments contain a substantial early and late risk of bleeding complications. [1] 
Drugs to induce thrombolysis have shown limited ability to treat thrombosis, as the 
likelihood of embolism becomes high. In certain cases such as large thrombi or 
particularly dangerous embolisms, surgery is also used to physically remove the clot. [39] 
 
1.3 Modeling of Thrombosis 
Because of the risks of many thrombosis-related disorders, there is a large 
demand for predictive models. However, taking into account the various chemicals and 
reactions involved, the distinct pathways for thrombosis such as platelet activation, and 
the relative importance of different factors presents a significant challenge in model 
development. Over the past few decades there has been significant work in this field, 
resulting in a large variety of models for thrombogenesis. Some common categories will 
be described here. 
Wall shear stress models use the correlation between local wall shear stress and 
platelet adhesion and aggregation. For subendothelium and collagen surfaces, platelet 
adhesion and aggregation have been observed to increase directly with shear rate. Areas 
of low wall shear stress are also predicted to give prolonged surface contact time and are 
associated with endothelial expression of various adhesive molecules. [24] 
Platelet-binding models focus on the chemical and mechanical links that form in 
platelet adhesion and aggregation. Guy (2002) develops a mathematical model that uses 
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collision dynamics and assumptions about platelet receptor occupancy to determine the 
capture probability, indicating whether two activated platelets will form a fibrinogen 
bond. The newly-formed bond must be strong enough to overcome hydrodynamic forces 
that act to separate the platelets. [15] Mori (2008) uses a computational model to simulate 
platelet adhesion and aggregation in the presence of von Willebrand factor and 
fibrinogen. The particle binding was modeled as spring forces using the Voigt model, and 
hydrodynamic forces were calculated from Stokesian dynamics. [28] 
Many models of thrombosis are geared towards determining the locations and 
likelihood of thrombus formation, and so they may use simplified models in order to 
produce a metric for thrombotic risk. Residence time models fall under this category. 
Flow residence time, broadly defined, is an indicator of how long a particle in a flow will 
remain close to its original location. Longest (2003) uses Lagrangian dynamics to 
introduce a near-wall residence time (NWRT) parameter calculated from flow velocities 
and particle dynamics, and demonstrates agreement with experimental data. The NWRT 
model also significantly outperforms the wall shear stress models used for comparison as 
well. [24] Residence time has also been modeled as a scalar that is transported by the 
flow via passive diffusion. A simplified residence time model of this kind was proposed 
by Narracott (2005) for determining thrombus formation risk in aneurysms. [29] Harrison 
(2007) combines a residence time scalar transport approach with the Lattice-Boltzmann 
method to provide a model that can be solved in complex and changing geometries. [16] 
Rayz (2010) simulated advection of a “virtual ink” in flow in a patient-specific aneurysm 
and found that thrombi are most likely to form in areas of high residence time and low 
wall shear stress. [32] 
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 Some of the more complex thrombosis models can be split up into Lagrangian 
and Eulerian models. Lagrangian models rely on particle tracking or numerical methods 
such as the Lattice Boltzmann method to solve the equations for platelet adhesion and 
aggregation. Harrison’s residence time model mentioned above also fits in this category. 
Filipovic (2008) uses the Discrete Particle Dynamics (DPD) algorithm to model 
interactions between blood plasma, platelets, and the vessel wall through adhesion and 
aggregation in a simple parallel plate shear flow. The conservative, dissipative, and 
random forces acting on the platelets are characterized by effective spring constants 
found from matching to experimental data. [10] Tamagawa (2009) developed a Lattice-
Boltzmann model to directly model the influence of shear rate on fibrinogen aggregation 
in a backward facing step flow. The activated fibrinogen is subject to higher surface 
tension forces to measure aggregation; platelets are not directly considered in this model. 
[37] The moving particle semi-implicit (MPS) method was used by Kamada (2010) to 
model three-dimensional thrombogenesis in a rectangular channel at low Reynolds 
number, again using a spring force to model adhesion and aggregation of platelets. The 
model investigated the formation and collapse of thrombus, including feedback reactions 
of thrombus development and flow. [18] 
Eulerian models of thrombus development typically use a set of coupled 
advection-diffusion equations to model the reactions between different chemical species. 
Sorensen (1999) simulates platelet adhesion and aggregation with agonist release and 
reactions to produce a model of platelet activation and deposition in flowing blood. The 
model uses a finite volume code and a coupled set of reactions for resting and activated 
platelets, agonists, thrombin, antithrombin, and other factors. [35] [36] Wootten (2001) 
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uses computational fluid dynamics, species transport, and a kinetic model of platelet 
activation and aggregation to model thrombosis over an atherosclerotic plaque. [42] 
Anand (2003) employed a finite difference code for the flow and solved coupled 
nonlinear transport equations for the coagulation cascade, fibrin production, and 
thrombosis inhibitors. The thrombus was modeled as a highly viscous fluid and clot 
formation and dissolution could be simulated. [1] Leiderman (2011) modeled activation, 
adhesion, and aggregation as reactions between different species of platelets. These 
reactions were coupled with the flow solution during numerical simulation. [22] Biasetti 
(2012) provides a model of the coagulation cascade as coupled reactions, supplies 
reaction rates for each, and simulates the production of thrombin in an abdominal aortic 
aneurysm (AAA) with the finite element method. [4] 
The most comprehensive thrombosis models are those categorized as multiscale 
models. These models can combine different scales and modeling algorithms, such as 
using both Lagrangian and Eulerian methods. Fogelson (2008) proposed a two-scale 
thrombosis model for a stenosed vessel. The microscopic scale model tracked the motion 
and interaction of individual platelets with the fluid, vessel walls, and other platelets. 
Activation was simplified in that platelets in proximity to the injured wall immediately 
became activated, and adhesion was represented by an elastic link formed between the 
wall and the platelet. The macroscale model looks at the same interactions in terms of 
concentrations of platelets and distributions of adhesive and cohesive links. Both models 
used the immersed boundary method to simulate the platelet masses in the flow as it 
provided a way to include the influence of aggregate growth on the flow and calculate 
shear stresses more readily. [11] Xu (2008) developed a separate multiphase model in 
17 
 
which the macroscale level employed the Navier-Stokes equations for the flow and 
advection-diffusion equations for chemicals, while the microscale model handled 
individual platelet activation, adhesion, and aggregation. The platelet interactions were 
solved using a cellular Potts model (CPM) at the microscale, which uses adhesion energy 




Coronary artery disease is considered the leading cause of mortality in the world. 
It involves the development of atherosclerotic lesions lining the artery wall, which as 
mentioned before, can go unstable and cause arterial thrombosis. Coronary arteries at risk 
are typically treated with percutaneous coronary intervention (PCI), which includes both 
balloon angioplasty of the vessel and stent implantation. [17] 
 
Figure 4: A stent placed inside an artery exhibiting stenosis. [31] 
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A stent is a tubular wire mesh structure that is designed to prop open a stenosed 
vessel over a long period of time. Initially, the treatment for coronary artery occlusion 
was to use only balloon angioplasty, a technique that inflates a balloon at the site of the 
stenosis and expands the artery locally to increase blood flow. However, balloon 
angioplasty by itself was not so effective because there was a very high risk for acute 
vessel closure immediately after the procedure due to elastic recoil, which could lead to 
acute myocardial infarction and other severe consequences just minutes after removal of 
the balloon. In addition, the balloon caused endothelial damage at the site of the 
angioplasty, which led to thrombosis. The first stent was implanted in a human body in 
1986, and the first coronary stents were used in 1991 to treat acute myocardial infarction. 
They were initially designed to scaffold the dilated artery and prevent it from closing 
after balloon angioplasty. Today the vast majority of PCI procedures still use balloon 
angioplasty and stent implantation. [17] 
It was discovered later that in-stent restenosis occurred in about 30% of coronary 
arteries with bare metal stents. This restenosis was due to two different phenomena. After 
angioplasty the damaged endothelium does induce a thrombotic response; however, this 
response is very effectively combated through antiplatelet and anticoagulant therapy 
delivered orally. But the response to injury, combined with the presence of a foreign body 
(the stent), triggers the formation and growth of neointima, a type of scar tissue that 
forms as inflammatory cells and then vascular smooth muscle cells are recruited to the 
site of the injury. [41] This complication was not as easily solved as early thrombosis 
effects. However, the development and implementation of drug-eluting stents (patented in 
1997) proved to be a very effective tool in preventing restenosis from neointimal 
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formation. [9] The drug-eluting stent is coated with drug-delivery vehicles to release 
chemicals slowly over time. The drug used to treat neointimal formation in clinical drug-
eluting stents is sirolimus (formerly rapamycin), which is a potent inhibitor of vascular 
smooth muscle cell proliferation that causes arterial stenosis. Local delivery of the drug 
with appropriate release kinetics has significantly reduced the chance of restenosis of the 
artery; a 2002 study showed reduction of in-stent restenosis from 35.4% to 3.2%. [41] 
 
1.4.2 Stent Thrombosis 
Stent thrombosis was a serious complication in early PCI procedures, but 
antiplatelet and anticoagulant therapies have significantly reduced the major risks 
associated with balloon angioplasty and stent implantation. Nevertheless, stent 
thrombosis is still a medical problem, especially over longer periods of time. 
Early stent thrombosis (EST) is defined as that which can be observed within the 
first 30 days after stent implantation. This was the complication that caused such high 
rates of restenosis and mortality in stent implantation in the 1980s and 1990s. The most 
effective tool in combating EST was found to be dual antiplatelet therapy with aspirin 
and the antithrombotic drug ticlopidine, which reduced the risk of early stent thrombosis 
to less than 2%. With the advent of drug-eluting stents, safety data showed similar or 
even lower rates of thrombosis with drug-eluting stents as compared to bare metal stents. 
However, a patient study showed a 1.4% rate of definite or probable stent thrombosis for 
both types of stents, indicating that although the risk of EST is low, it is nonzero. These 
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risks are increased by procedural errors in the PCI procedure, pre- and post-treatments, 
and improper drug therapy delivery to the target. [6] 
A complication that was discovered in the last two decades is that of late stent 
thrombosis (LST), defined as thrombosis occurring between one month and one year 
from stent implantation. While most of the risk factors for early stent thrombosis are 
procedural, those for LST are more often patient-specific, such as adverse cardiac events, 
increased rates of platelet aggregation, and impaired response to antiplatelet therapy. 
Obviously, discontinuation of the antiplatelet therapy is one of the biggest risk factors for 
LST. However, late and very late stent thrombosis (longer than one year after stent 
implantation) actually occur more commonly in drug-eluting stents than in bare metal 
stents. The reason for this appears to be delayed healing of the endothelium due to the 
drug-polymer combination released from the stent, which becomes a large risk factor if 
antiplatelet therapy is discontinued. If these complications are discovered, immediate 
action through another PCI procedure is the best therapy of choice to treat the 
thrombosis. [40] 
 
1.4.3 Numerical Studies 
Various models have been developed to investigate different aspects of stent 
implantation, local hemodynamics, and drug delivery from stents. One area of stent 
modeling research is to model the mechanical forces and interactions between the stent 
and the blood vessel. Kiousis (2007) developed a numerical model for the fissuring and 
dissection of the atherosclerotic plaque lining a human iliac artery in response to balloon 
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angioplasty and stent placement. A three-dimensional finite element model was 
employed to model the angioplasty and stent contact forces, induced stresses on the 
arterial wall, and the gain in lumen area. [20] Zahedmanesh (2010) uses a three-
dimensional finite element model to calculate the deformation and stresses present in the 
interaction between an expanding balloon and stent system and an arterial wall. [45] 
Other models concern themselves primarily with the flow field over stented 
arteries. Berry (2000), one of the earlier numerical models of stents, is split into an 
experimental and a numerical section. The experiment uses dye visualization to 
investigate flow and shear rates in a synthetic coronary artery with an inserted stent. The 
numerical section uses computational fluid dynamics to model a two-dimensional 
pulsatile flow over the wires of a stent, and determines velocity and shear rate gradients 
in the channel for various different stent geometries. [3] 
A third category of models specifically examines drug-eluting stents and analyzes 
how the drug is transported in the artery to its target tissue. Sakharov (2002) develops a 
mathematical model and simple numerical model for a stent-delivered drug that binds to 
vascular tissue. Diffusion properties of the drug and the mechanisms of binding are 
varied to study their effect on the biodistribution and pharmokinetics of the drug. [34] 
Zunino (2009) details a comprehensive model of drug distribution from a stent that 
includes mechanical action of the stent on the vascular wall and interaction of blood flow 
on drug release. The three-dimensional finite difference model is able to analyze the 
diffusion of the drug into the vascular tissue and how it is affected by these different 
factors. [46] Pontrelli (2010) investigates drug delivery effectiveness into the vascular 
tissue, treating the wall as four layers (endothelium, intima, elastic lamina, and media) 
22 
 
that are porous to the drug and have their own diffusive properties. Through this model, 
analytical solutions for drug concentration and mass are obtained in space and time. [31] 
Vairo (2010) develops another comprehensive, multiscale and multidomain model for a 
drug-eluting stent that takes into account tissue microstructure and local hemodynamics 
to describe drug transport in stent coating, arterial tissue, and blood flow.  The 
axisymmetric COMSOL model solves for flow velocity fields and drug concentrations 
given release dynamics, input blood flow, and wall porosity conditions. [38] 
 
1.5 Objectives 
There are two major objectives of the current study. First, this work will develop a 
numerical model for stent thrombosis based on computational fluid dynamics (CFD). The 
model will include an incompressible flow solver utilizing a sharp interface immersed 
boundary method to solve for the flow in a two-dimensional artery with stent geometry. 
This will be coupled to a scalar transport solver to solve the coupled advection-diffusion 
equations that describe the coagulation cascade and platelet adhesion/aggregation. 
Second, this numerical model will be applied to investigate the effectiveness of an 
anticoagulant based on its method of delivery. Antithrombin-bound heparin, an inhibitor 
of the coagulation cascade, will be administered both through the flow and through drug-
eluting stents to the affected thrombogenic tissue. The model will be applied to both 
steady and pulsatile flow to compare the two delivery methods and quantitatively 
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evaluate their effectiveness and efficiency in preventing the local platelet aggregation 




In this study, we use a computational model that couples an incompressible flow 
solver with a convection-diffusion-reaction equation model of the coagulation cascade 
and the Eulerian model of platelet activation and aggregation. We will investigate how 
platelet activation and aggregation are affected by the delivery of an anticoagulant both 
through the blood flow and through a drug-eluting stent for a two-dimensional stented 
artery. 
 
2.1 Thrombosis Model 
The model for thrombosis will incorporate the work of Biasetti (2012) and 
Leiderman (2011). Biasetti’s model of the coagulation cascade will be used to determine 
thrombin concentration in the stented artery from a specified distribution of tissue factor 
representing the endothelium injured from balloon angioplasty. This thrombin 
concentration will then be used as an input to Leiderman’s model of platelet deposition, 
where it will be used to activate mobile platelets in the blood. Leiderman’s model will 
then describe the interplay between different species of platelets, the blood flow, and the 
affected endothelial wall in order to generate platelet adhesion and aggregation in 




2.1.1 Coagulation Cascade 
Biasetti (2012) developed a fluid-chemical model to simulate the extrinsic 
pathway of the coagulation cascade through a series of coupled convection-diffusion-
reaction equations. The model encompasses the various plasma-phase and surface-bound 
chemical species and reactions in the coagulation cascade. It was proposed initially to 
model thrombus formation in an abdominal aortic aneurysm, and was coupled with a 
shear-thinning incompressible flow model and solver for blood. In the current study, we 
employ the chemical modeling approach of Biasetti but use a Newtonian fluid model. 
The coagulation cascade model begins after the binding of factor VIIa from the 
blood plasma with tissue factor (TF) on the subendothelium surface to form TF:VIIa. 
This begins a set of 16 distinct chemical reactions involving 18 different chemical 
species. The coupled convection-diffusion-reaction equations for the chemical species are 
written as: 





u       (1) 
where ic  for 18,,2,1 =i  represents the species concentration, iD  is the species 
diffusivity, and u  is the flow velocity vector given from the Navier-Stokes equations 
(more information on this will be given in section 2.2.1). The concentration vector 
contains the 18 species in the following order: IX (antihemophilic factor B), TF:VIIa 
(tissue factor complex), IX:TF:VIIa ,IXa, X (Stuart-Prower factor), X:TF:VIIa, Xa, 
VIIIa:IXa, X:VIIIa:IXa, V (proaccelerin), Va, VIII (antihemophilic factor), VIIIa, IIa 
(thrombin), II (prothrombin), Va:Xa, II:Va:Xa, and mIIa. The reaction terms iR  are 
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defined by the individual 16 rate equations (equations (2)-(13)) and stoichiometric matrix 
S . These specified reactions are all modeled to occur in the blood flow, not on any 
specific membranes or surfaces. Overall, the transport equation contains diffusion, 
reaction, and convection for each of the 18 chemical species. Table 1 contains the 18 
reaction rates for the chemical equations. 
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  (4) 
IXa  Xa  Xa  IX 15k +→+   (5) 
Va  Xa  Xa  V 1k +→+   (6) 
VIIIa  Xa  Xa  VIII 3k +→+   (7) 
Va  IIa  IIa  V 2k +→+   (8) 
VIIIa  IIa  IIa  VIII 4k +→+   (9) 









  (10) 
II  Xa:Va  Xa:Va  mIIa 5k +→+   (11) 
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  (13) 
 
Rate Constant Value 
1k  2 × 104 mol-1 m3 s-1 
2k  2 × 104 mol-1 m3 s-1 
3k  1 × 104 mol-1 m3 s-1 
4k  2 × 104 mol-1 m3 s-1 
5k  1 × 104 mol-1 m3 s-1 
6k  1 × 105 mol-1 m3 s-1 
7k  1 × 104 mol-1 m3 s-1 
8k  4 × 105 mol-1 m3 s-1 
9k  0.005 s-1 
10k  0.4 s-1 
11k  0.3 s-1 
12k  1.15 s-1 
13k  8.2 s-1 
14k  32 s-1 
15k  1 × 102 mol-1 m3 s-1 
16k  24 s-1 
17k  44 s-1 
18k  0.001 s-1 
19k  70 s-1 
Table 1: List of reaction rates for coagulation cascade model. 
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= , where 
dt
d  represents the total derivative, ijS  is the 18 × 16 stoichiometric 
matrix mentioned  above and jr  is the vector for the reaction rates in the 16 equations. 
The stoichiometric matrix coefficients determine the reactants and products of each 
equation as well as their ratio, and in this way reaction kinetics are incorporated into this 
time-evolving coagulation cascade model. 
If the anticoagulant heparin is present, the model incorporates it in its active form 
bound with antithrombin to form AT:H. This adds a 19th species to the concentration, an 
extra diffusivity, and additional reaction vector terms in the convection-diffusion-reaction 
equations, and also changes the stoichiometric matrix to represent the inhibitory effect of 
the AT:H complex on various reactions in the coagulation cascade as shown below in 
Figure 5. The additional reactions are found in equations (14)-(16), and reaction rates for 
high-affinity heparin are found in table 2. 
H:AT:Xa  H:AT  Xa 20k→+  (14) 
H:AT:IXa  H:AT  IXa 21k→+  (15) 





-1 0 0 0 0 0 -1 0 0 0 0 0 0 0 0 0 0 0 0 
-1 1 -1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1 -1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
0 1 0 0 0 0 1 0 0 0 0 0 0 0 -1 0 -1 0 0 
0 0 -1 0 -1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
0 0 1 -1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 -1 0 -1 0 
0 0 0 0 -1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 
0 0 0 0 1 -1 0 0 0 0 0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 -1 0 -1 0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 -1 0 0 0 
0 0 0 0 0 0 0 0 -1 0 -1 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 1 0 1 0 0 0 -1 0 0 0 0 
0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 -1 
0 0 0 0 0 0 0 0 0 0 0 -1 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 0 0 -1 1 0 0 1 0 0 0 
0 0 0 0 0 0 0 0 0 0 0 1 -1 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 0 0 0 1 -1 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 -1 -1 -1 
Figure 5: The stoichiometric matrix ijS  used for the reactions of the coagulation 
cascade and additional AT:H reactions. 
 
Rate Constant Value 
20k  2 × 104 mol-1 m3 s-1 
21k  140 × 103 mol-1 m3 s-1 
22k  37 × 103 mol-1 m3 s-1 
Table 2: List of reaction rates for the high-affinity heparin reactions in the 






IX 90 × 10-6 mol m-3 
TF:VIIa 1 × 10-6 mol m-3 
X 170 × 10-6 mol m-3 
V 20 × 10-6 mol m-3 
VIII 0.7 × 10-6 mol m-3 
VIIIa 0.1 × 10-6 mol m-3 
II 1.4 × 10-3 mol m-3 
AT:H 60 × 10-6 mol m-3 
Table 3: Initial species concentrations of inputs for coagulation cascade model. 
All other species have zero initial concentrations. 
Table 3 gives typical concentrations of the model inputs as provided by Biasetti, 
as well as a typical value for heparin concentration in the blood. Additionally, the 
diffusivity of the chemical species in the cascade according to Leiderman is 
s/cm105 27−× . The net result of this extrinsic coagulation cascade pathway model is the 
formation of IIa thrombin, which among other roles is used to activate platelets in the 
bloodstream. 
 
2.1.2 Platelet Model 
In Leiderman’s work, a comprehensive platelet model is developed that considers 
the coagulation cascade, platelet activation, adhesion, aggregation, and even the blood 
flow interactions with the growing thrombus mass. Only the platelet model is used in this 
essay; the coagulation cascade model in Biasetti is substituted for blood coagulation and 
thrombin production, and the thrombus mass in our case is small and flat enough to 
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minimally impact the blood flow. This model was tested for a two-dimensional parabolic 
blood inflow velocity profile, which is quite similar to the boundary conditions used in 
this stent model described in 2.3.2. Combining this model with the Biasetti coagulation 
cascade model will provide a full platelet deposition model that corresponds to thrombus 
formation. 
Leiderman’s model categorizes platelets in four distinct categories. Mobile, 
unactivated platelets umP ,  are the free-flowing latent platelets naturally found in the 
bloodstream. Through activation by thrombin or ADP (not used in this essay’s model), 
these are converted to mobile, activated platelets amP , . Platelets directly attached to the 
injured vascular wall through adhesion are subendothelium-bound activated platelets 
aseP , , and platelets attached to other bound platelets are platelet-bound activated abP , . 
The transport equations for these four species are given by equations (17)-(20): 
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∂ x     (20) 
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where u  is again the flow velocity vector, D  is the platelet diffusivity, maxP  is a 
maximum number density for platelets (set to 71067.6 × /mm3), and IIac  is the 
concentration of IIa thrombin. The function ( ) ( )( )TTW φπφ −= 1tanh  is a function of 
platelet fraction that acts to slow down platelets moving through a platelet-rich region 
due to their size. The coefficients adhk  and cohk  are used in adhesion and cohesion of 
platelets, with the spatial dependence of the former being used to ensure that adhesion 







= ∗1  is 
used, with placIIak  and 
∗c  being positive constants. The cohesion term also has a function 
( )ηg  that represents a binding affinity function that governs the rate and distance at 
which platelets can bind to each other. In Leiderman’s model this was done with the 
release of a virtual scalar η  that was secreted from subendothelium-bound and platelet-
bound platelets, which would decay at some distance away from its source. This allowed 
bonds of a specified length to form between platelets. However, the model that was used 
for the stented artery used a numerical alternative to this virtual scalar approach, which is 
described in 0. 
Rate constants and other parameters were fixed for this model as in section 2.3.3. 
Leiderman provides a diffusivity for platelets of s/cm105.2 27−× . Typical human 
platelet counts are in the range of 312 m/10450150 ×−  for mobile unactivated platelets. 
Through this model bloodborne unactivated platelets will be activated by thrombin 
produced in the blood from the Biasetti model, and then those platelets will be able to 




2.2 Numerical Methods 
Numerical simulation of the coagulation cascade and platelet models above in a 
biological flow involves the fluid dynamics of a stented artery, the transport of 
biochemical species in such a flow, and the interaction of the species with each other. 
This problem requires a high-fidelity incompressible flow solver coupled with an 
advection-diffusion solver for the transport equations that describe the various 
biochemical reactions of thrombosis. In this section, details about the incompressible 
flow solver and the scalar transport solver are provided. 
 
2.2.1 Incompressible Flow Solver 
The flow solver in this study is the one described in Mittal (2008). [26] The fluid 












































1      (22) 
where iu  are the velocity components for 3,2,1, =ji  (although we only consider a two-
dimensional system, the solver is able to handle three-dimensional problems as well), p  
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is the pressure, ρ  is the fluid density, and ν  is the kinematic viscosity. The boundary 
conditions for velocity are the no-slip condition on the walls of the channel, a zero-
gradient outflow, and specified inflow conditions that will be described later. These 
equations are discretized appropriately in time and space to solve them on a Cartesian 
grid. 
Equations (21)-(22) are discretized in space with a cell-centered, collocated finite 
difference scheme. Here, the values of velocity and pressure are stored at the centers of 
all cells. In addition, a set of face-center velocities iU  are calculated at each time step by 
averaging the values at each grid node. The equations are discretized in time by using the 
fractional step method of Van-Kan, which is described below. 






































































































−+ 11         (25) 
ppp nn ′+=+1         (26) 
The Van-Kan fractional step method takes the velocity from niu  to 
1+n
iu  in a series 
of three substeps and an intermediate step ∗iu . In the first substep, the modified 
momentum equation (23) derived from (22) is solved. Here the advective and diffusive 
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terms have been discretized with a Crank-Nicolson scheme, and 
xδ
δ  represents a second 
order difference operator. The face-center velocities are calculated by averaging the 
values at the grid nodes to either side of the face. Using face-center velocities eliminates 
the problem of odd-even decoupling that is associated with cell-centered, collocated 
grids. 
In the second substep, a pressure correction term p′  is calculated from the newly-
computed face-center velocities. This equation is obtained from combining the 
momentum equation (22) with the divergence-free velocity condition (21). As a result, 
proper numerical discretization ensures that the final velocity 1+niu  will be divergence-
free. This Poisson equation for the pressure is solved for Neumann boundary conditions 
at all boundaries. The Poisson solver employs the multigrid method with a Gauss-Seidel 
line-SOR smoother, a method that is known to be highly efficient and quickly 
convergent. Its convergence scales almost linearly with the number of grid points. 
After the pressure correction has been obtained, the final substep is to update the 
pressure and velocity from the intermediate step to the 1+n  step. Equations (25) and (26) 
illustrate this procedure for velocity and pressure. The updated velocities satisfy mass 





Immersed Boundary Method 
To deal with the geometry of the curved stent wire structures, the solver employs 
a sharp interface immersed boundary method to apply the stent boundary conditions of 
no-slip and no-penetration onto the grid. Immersed boundary (IB) methods generally fall 
into two categories: continuous and discrete forcing approaches. Continuous forcing IB 
methods introduce a forcing term to account for the immersed boundary into the 
continuous governing equations, and then discretize the result for numerical solution. 
Discrete forcing methods, such as the one used here, first discretize the governing 
equations disregarding the immersed boundary, and then modify the discretization in 
cells close to the immersed boundary to account for its presence. In the current model, 
this is done with the use of ghost cells with values determined to match boundary 
conditions locally. 
The stent geometry is represented by an unstructured mesh of triangular elements 
generated using the meshing software Gambit. First, the grid cells are separated into 
“solid cells” and “fluid cells:” those whose cell centers lie inside the solid boundary 
defined by the mesh, and those whose cell centers lie outside the body. This is done for a 
specific node by determining the surface element closest to the node and then taking the 
dot product of the surface normal n̂  with the vector p  extending from the surface 
element to the node. A positive value of np ˆ⋅  indicates that the node is outside the solid 
body, and a negative value shows that it lies within the body. After this, cells are 
identified as “ghost cells” from the solid cells if they have a neighboring fluid cell in any 
37 
 
direction. Figure 6 shows the identification of solid, fluid, and ghost cells for a curved 
boundary. 
 
Figure 6: A depiction of the sharp interface immersed boundary method used in 
this simulation. The fluid, solid, and ghost cells (GC) are depicted, as well as the image 
points (IP) and boundary intercepts (BI) utilized by the solver. This figure has been taken 
from Mittal (2008). [26] 
The procedure now is to obtain a value for each ghost cell that will ensure implicit 
satisfaction of the boundary conditions for the solid body. To do this, an appropriate 
boundary intercept is found for the ghost cell such that the intercept is both as close to the 
ghost cell node as possible and the intercept vector is as normal to the surface as possible. 
After obtaining the intercept, a “probe” is extended into the fluid domain to identify an 
image point such that boundary intercept is the midpoint of the segment connecting the 
ghost cell and image point. It is important that the image point be located close to the 
boundary such that it accurately reflects the local flow conditions of the boundary. Figure 
6 shows the placement of boundary intercepts and image points for sample ghost points 












Next, we determine a value for the image point by using bilinear interpolation 
(trilinear in three dimensions) of the values of the nodes surrounding the image point. 
This is represented for each image point in Figure 6 as a gray box. This gives a value for 
the image point in the form ∑=
i
iiIP φβφ , where i  represents the nodes used for 
interpolation and iβ  are the respective interpolation coefficients. After the value of the 
image point is obtained, it is straightforward to determine a ghost cell value that 
implicitly satisfies boundary conditions on the surface. For a Dirichlet condition, 
IPBIGC φφφ −= 2  determines the value of the ghost cell from the known value at the 










δφφφ , where l∆  is the 









δφ  is the known flux at the boundary. These expressions are all 
second order accuracy, and can be used to solve the velocity and pressure equations at the 
stent wire boundaries in this simulation.  
 
2.2.2 Scalar Transport Solver 
The convection-diffusion-reaction equation (1) is coupled to the incompressible 
flow solution via the term u . At each time step, the flow solution is then used in the 
calculation of the coupled equations for transport of each chemical species. Species are 
coupled by writing them into a nonlinear system of equations for a species concentration 
vector at each cell node. This equation is solved at the cell centers using a fully explicit 
fourth-order Runge-Kutta time discretization, with the convection term being spatially 
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discretized by the following second-order upwind scheme for the first derivative. At each 
time step, the first order ODE in (28) is solved by first calculating the intermediate 
quantities in (29)-(32) and then advancing the concentration from time step n  to 1+n  as 
in (33). Here ),( tcf  represents the right hand side of (28), which is spatially discretized 
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2.3 Simulation Parameters 
The model described above is applied to the specific problem of a stented artery 
through the development of a channel and stent geometry, flow boundary conditions, and 
chemical species boundary conditions. The study examines both steady and pulsatile flow 
through a two-dimensional channel representing a coronary artery containing a series of 
stent wires. For both types of flow the model will simulate three cases: 
a. A bare metal stent control case with no anticoagulant. 
b. A bare metal stent with antithrombin-heparin complex anticoagulant 
delivered through the flow. 
c. A drug-eluting stent secreting the same antithrombin-heparin complex into 
the flow. 
 
2.3.1 Channel and Stent Geometry 
 
Figure 7: A diagram of the 2D half-channel with stent geometry used in 
numerical simulation. The lengths are normalized in accordance with Berry (2000) such 
that the height of the half-channel (1.0) is 1 mm. 
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The numerical study describes the coronary artery as a two-dimensional channel, 
and uses the work of Berry (2000) as a foundation. [3] A number of simplifications are 
made in order to reduce the computational cost of the simulations. First, the tubular 
lumen is simplified to a 2D channel. Second, the flow in the channel is assumed to be 
symmetric about the centerline and only the bottom half of the channel is simulated. 
Figure 7 shows a diagram of the full channel simulated. The left and right sides indicate 
inflow and outflow, and on the bottom there is a boundary extending from the wall to 
indicate the geometry of the struts of the stent. The strut wire cross-section is circular, but 
Berry’s work looked at the overlapping region of two stent struts, with the bottom wire 
being embedded slightly into the vessel wall. Here, this structure is simplified to the one 
seen in Figure 8 for the purposes of computational simplicity. Simulations were carried 
out with a two-wire structure that more closely resembled Berry’s stent geometry, but no 
major differences were noted in the flow properties between that structure and the one 
used in the current study. 
 
Figure 8: A diagram of the stent structure geometry with labeled dimensions 
overlaid on the computational grid. The lengths are normalized such that 1.0 represents 1 
mm. 
The length and height of the half-channel were taken to be 2.765 and 1.0 







half-channel represents 1 mm. The width and spacing of the stent struts were taken from 
Berry’s work as 079.0=w and 237.03 =w , and the height of the structures was 0.1106. 
[3] The first stent structure is located at 395.05 =w  as shown in Figure 7. Figure 8 shows 
the relevant stent measurements. The simulation was performed on a 512 × 128 mesh 
with uniform spacing in the horizontal direction and geometrically-expanding intervals in 
the vertical direction past the height of the stent. This mesh was chosen such that the 
width of the stent structures would span about 15 grid horizontal grid lengths, which was 
assumed to be fine enough to capture all relevant features of the flow and transport 
model. 
 
2.3.2 Flow Properties and Boundary Conditions 
The simulations are performed for both a steady flow and a pulsatile flow. 
Obviously, blood flow in the coronary artery is inherently pulsatile, but here both cases 
will be studied to investigate the effect of pulsatile flow on any trends observed. The two 
dimensionless numbers of note are the Reynolds number and the Womersley number. 
The Reynolds number indicates the ratio of inertial to viscous forces in the flow, and is 
defined here by 
ν
LU c=Re  where cU  is the average fluid velocity at the inflow, L  is the 
channel height (here 0.2=L ), and ν  is the kinematic viscosity of the fluid. The 
Reynolds number used was 160Re =  for a typical coronary artery under resting 
conditions for the heart, and is taken from Berry (2000). The Womersley number relates 
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Wo L=  
where ω  is the angular frequency of the flow pulsation. For the current simulations, the 
value used is 7.2Wo =  for resting conditions, in accordance with the work of Berry 
(2000). [3] 
 
Figure 9: An illustration of sample flow profiles for Womersley numbers of 0.1, 
1, and 10. This figure has been taken from Loudon (1998). [25] 
A steady input flow was constructed using the fully developed Poiseuille flow 
solution for a channel. The pulsatile flow naturally occurring in the coronary artery is a 
reflection of varying pressure gradient, whose solution for pipe flow and a constant 
frequency change is known as the Womersley profile. However, in this study the pulsatile 
flow will be assumed as a sinusoidal form of the Poiseuille flow profile, since the 
Womersley number is not very high. Figure 9 shows why this is a reasonable assumption 
to make, as the Womersley number of 2.7 is closest to the 1=Wo  case where the flow is 
still parabolic. This treatment also provides easier implementation and faster simulation 
times. The amplitude of the pulsatile component is taken to be half that of the steady 
flow. Equations (27) and (28) are used for the steady and pulsatile input flows 
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respectively, where cU  is the mean velocity at the inflow used in the Reynolds number 
expression. 
( )yyUyu csteady −= 0.25.1)(        (34) 
( ) ( )( )tyyUyu cpuls πω2sin5.00.10.25.1)( +−=     (35) 
The velocity cU  and frequency ω  were determined from simulation parameters and the 
definitions of Reynolds and Womersley number. Table 4 gives the values of some of 
these simulation parameters for the flow.  
Parameter Values 
Kinematic viscosity ν  0.0033 
Mean velocity cU  0.2640 
Centerline velocity )0.1( =yu  0.3960 
Characteristic time cchannel Ul /  10.4735 
Angular Frequency ω  0.02451 
Period ω/1  40.8047 
Table 4: Dimensionless simulation parameters used for the flow in this study. 








uu . At the top boundary, the “centerline” of the channel flow, a symmetry 








2.3.3 Thrombosis Model Boundary Conditions 
For the thrombosis model, the inputs needed are tissue factor sources, heparin 
sources, and the concentrations of inactivated platelets and various bloodborne 
intermediates in the coagulation cascade. The tissue factor is secreted from the injured 
tissue wall after balloon angioplasty. In the current simulation it is specified as a region 
along the bottom wall spanning from 0.4000 to 2.2910, an interval that encloses all of the 
stent structures. Using an immersed boundary object along the bottom wall with node 
spacing smaller than the grid spacing, the value for the tissue factor concentration of 
100.0 is applied at each node (all simulation concentrations have been scaled such that 
unity in the simulation represents 1 × 10-6 mol m-3). 
The study investigates two different methods of heparin delivery. For the case of 
flow-delivered heparin, the concentration of AT:H complex is specified initially 
everywhere in the fluid domain. Additionally, the same value is applied as a Dirichlet 
condition for AT:H concentration on the inflow boundary. For the case of heparin 
delivered by drug-eluting stents, the AT:H complex concentration value is specified as a 
Dirichlet condition on the boundaries of the stent struts. Just as with tissue factor, the 
value is specified at the nodes of the structure, and the node spacing is smaller than the 
grid spacing. In both cases the applied value of AT:H complex is 60.0. 
The inactive platelet number density, as well as the concentrations of selected 
intermediates in the coagulation cascade that reside naturally in the blood, are also 
specified initially throughout the fluid domain. Just as with flow-delivered heparin, a 
Dirichlet condition is applied at the left inflow boundary with the same value as the initial 
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concentration. The values of all of these species can be seen in table 5. All other species 
have zero initial concentration. 
Platelet species and chemical species in this model have different diffusivities, 
and this is taken into account through the Schmidt number. The Schmidt number is the 
ratio of momentum diffusivity to mass diffusivity, and is defined here as 
D
ν
=Sc . It is 
taken to be 400.0 for all chemical species and 4000.0 for all platelet species. The high 
Schmidt numbers should not cause stability concerns as the use of a second-order 
upwinding scheme will suppress numerical instabilities that may arise. A summary of all 
of these concentrations and Schmidt numbers is found in table 5. 
Species Initial Concentration/Number Density Schmidt Number 
IX 90.0 400.0 
TF:VIIa 100.0 400.0 
X 170.0 400.0 
V 20.0 400.0 
VIII 0.7 400.0 
VIIIa 0.1 400.0 
II 1400.0 400.0 
AT:H (in appropriate cases) 60.0 400.0 
Mobile, unactivated platelets 0.003748 4000.0 
All other platelet species 0.0 4000.0 
All other chemical species 0.0 400.0 
Table 5: Summary of simulation initial conditions and boundary conditions for 
the thrombosis model. The coagulation cascade species concentrations are scaled such 
that unity represents 1 × 10-6 mol m-3, and the platelet species number densities are 




3 Results and Discussions 
This section details the results of the thrombosis model simulation. First, the 
results of the flow simulation in the stented channel are presented for steady and pulsatile 
input flow profiles. Then, results from the modeling of the coagulation cascade and 
platelet adhesion and aggregation are shown for steady and pulsatile flow. For each flow 
type, three cases are investigated: a bare metal stent with no anticoagulant, a stent with 
flow-delivered AT:H complex, and a drug-eluting stent that delivers AT:H locally. 
 
3.1 Flow Simulation Results 
3.1.1 Steady Flow 
 
Figure 10: Pressure contours and streamlines for steady flow. After time 5.12=t
shown, the flow becomes steady in time. 
The simulation results for steady parabolic input flow are shown above. Figure 10 
shows the pressure contours and streamlines for the flow. The time 5.12=t  is used, after 
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which the solution is steady. Comparing this to the characteristic time in Table 4 of 
10.4735, there is good agreement as this is the first sampled time step after the 
characteristic time. 
Inspecting the streamlines shows the characteristic recirculation zones between 
stent structures that were observed in Berry (2000). [3] Between each pair of structures is 
a clockwise-rotating vortex. These streamlines show that although the stent geometry was 
simplified from the one in Berry’s paper, the major flow structures are still captured in 
this simulation.  
 
 
Figure 11: Horizontal velocity contours for steady flow. The flow is steady after 




Figure 12: Plot of horizontal velocity profiles at three locations for steady flow. 
The inflow horizontal velocity is the simulation velocity at the cell centers immediately 
adjacent to the inflow, while the outflow horizontal velocity is the simulation velocity at 
the cell centers adjacent to the outflow. The stent horizontal velocity is the velocity 
through the line that cuts through the head of the first stent wire. 
Figure 11 shows horizontal velocity contours for the entire domain, which 
indicates a roughly parabolic profile throughout the domain as expected. Figure 12 
contains horizontal velocity profile plots at three locations: the inflow, outflow, and 
location of the first stent. Inspection shows that the no-slip boundary condition is obeyed 
at all three locations, and also shows a slight change in profile as the flow traverses the 
computational domain. Specifically, flow is channeled from the near-wall region towards 










Figure 13: Pressure contours and streamlines for pulsatile flow. Four times are 
shown over the course of the simulation period: (a) 0.40=t , (b) 5.52=t , (c) 5.62=t , 
and (d) 0.75=t . 
The simulation results for pulsatile flow are now shown. To illustrate the time 
dependence throughout the cycle period 40.8047, four time instants at 40.0, 52.5, 62.5, 
and 75.0 are chosen. Figure 13 shows the pressure contours and streamlines for pulsatile 
flow. The periodic pressure changes over time can be observed. At its peak in figure 13 
(b), the pressure drop is roughly twice the magnitude of the drop for the steady case, and 
at its low point in figure 13 (a) it is almost zero. Throughout the course of the simulation 
the recirculation zones can be observed as in the steady case. However, at the end of the 
simulation period as shown in figure 13 (d), the streamlines to the right of the last stent 









Figure 14: Horizontal velocity contours for pulsatile flow. Four times are shown 










Figure 15: Plot of horizontal velocity profiles at three locations for pulsatile flow. 
The inflow horizontal velocity is the simulation velocity at the cell centers immediately 
adjacent to the inflow, while the outflow horizontal velocity is the simulation velocity at 
the cell centers adjacent to the outflow. The stent horizontal velocity is the velocity 
through the line that cuts through the head of the first stent wire. Four times are shown 
over the course of the simulation period: (a) 0.40=t , (b) 5.52=t , (c) 5.62=t , and (d) 
0.75=t . 
Figure 14 shows the horizontal velocity contours over the simulation period. 
Upon comparison to the pressure contours, it can be observed that the peak magnitudes 
for velocity lag behind those for pressure. This behavior indicates that the simulation 
method used is effective for simulating a pressure-driven flow even though the time-
varying pressure drop was not used for the boundary condition at the inflow and outflow. 
Figure 15 shows the horizontal velocity profiles over time again at three locations: the 
inflow, outflow, and location of the first stent. From figure 15 (c) we observe that the 
peak horizontal velocity is about 1.5 times that of the steady case, and from figure 15 (a) 
that the lowest horizontal velocity is roughly 0.5 times that of the steady case. This is 
exactly what is expected from our specified input flow. Also, we observe that at the 
outflow, the curvature of the flow closer to the wall is changing over time. These changes 
resemble the Womersley profile that is typical for flows created from pulsatile pressure 
drops. However, the flow over the first stent strut in figure 15 follows more of a parabolic 
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shape, whose curvature indicates that the stent struts are not interacting with a developed 
Womersley flow. This is a difference between this simulation and biological blood flows, 
but its effect is assumed to be minor on the results obtained. 
 
3.2 Thrombosis Modeling Results 
The results from modeling the coagulation cascade and platelet clotting are 
presented in this section. The coagulation cascade is triggered by the release of tissue 
factor from the area of the wall specified as injured from the angioplasty procedure. 
Platelet species are tracked throughout the model, including mobile, activated platelets 
and platelets bound to the wall or to other platelets. The simulation is run for bare metal 
stents with no added heparin complex, AT:H delivered through the flow, and stent-
delivered AT:H in order to determine the effectiveness of both anticoagulant delivery 




3.2.1 Steady Flow 
 
Figure 16: Plot of total tissue factor concentration in the domain over time for 
steady flow. 
Figure 16 plots the total tissue factor concentration in the computational domain 
over time. It monotonically increases and plateaus over time as expected for the fixed-
value of tissue factor at the boundary. All of the analysis is performed after the scalar 
concentrations have reached a steady state. 
 
 
Figure 17: Tissue factor contours at time 0.500=t  for steady flow. The inset is 
zoomed on the region between struts 5 and 6, and includes streamlines for comparison. 
Figure 17 shows contours of tissue factor at time 500.0 for steady parabolic 
inflow. The figure indicates that tissue factor has diffused into the flow from the lower 
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wall between 400.0=x  and 291.2=x , where advection from interaction with the flow 
(diffusion is a lesser effect based on the high Schmidt numbers) leads to the distribution 
observed. Tissue factor is advected downstream, but the areas of high concentration 
remain close to the stent bodies. In between the struts, the highest concentration of tissue 
factor is found near the bottom of the leading strut, as the tissue factor near the trailing 






Figure 18: AT:H contours for (a) flow-delivered AT:H, and (b) drug-eluting 
stent-delivered AT:H at time 0.500=t  for steady flow. The insets are zoomed on the 
region between struts 5 and 6, and include streamlines for comparison. 
Figure 18 shows the antithrombin-heparin complex contours at time 500.0 for two 
cases: in (a), the AT:H is delivered by the flow through a Dirichlet condition on the left 
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boundary and in (b), the AT:H is delivered by a drug-eluting stent, modeled through a 
boundary condition on the stent struts. In both cases the anticoagulant diffuses into the 
flow, where it is transported primarily through advection through the domain. Figure 18 
(a) shows that although there is a high concentration of heparin in the domain, it does not 
penetrate well into the region between the struts. Additionally, a very low concentration 
of AT:H is observed near the bottoms of the trailing edges of several stent struts (which 
also corresponds to the areas of maximum thrombin concentration as shown below) as 
the anticoagulant is advected into each recirculation zone from the left. The AT:H in the 
bulk flow is not effective in penetrating the vortices between stents to enter these regions, 
and whatever does enter is used up immediately in reactions with coagulation cascade 
intermediates. However, in figure 18 (b) there are higher AT:H concentrations in these 
regions with the drug-eluting stent, which means that it is not being used up entirely and 
that AT:H from the stents is more effectively moved by the flow to replace the 
anticoagulant used up in reactions. 
 
 




Figure 19 shows the total AT:H concentration in the domain for both delivery 
methods. In both cases, the concentration increases and then plateaus, with values of 
roughly 155 and 6 for the flow-delivered and drug-eluting stent-delivered anticoagulant 
cases respectively. The drug-eluting stent releases significantly less anticoagulant into the 
channel than flow delivery, but a greater concentration is nonetheless delivered to the 











Figure 20: Thrombin contours for (a) bare metal stent, (b) flow-delivered AT:H, 
and (c) DES-delivered AT:H at time 0.500=t  for steady flow. The insets are zoomed on 
the region between struts 5 and 6, and include streamlines for comparison. 
 
Figure 21: Plot of total thrombin concentration over time in the domain for bare 
metal stent, flow-delivered AT:H, and DES-delivered AT:H for steady flow. 
Figure 20, depicts the contours of thrombin, mobile activated platelets, and bound 
platelets respectively throughout the domain at time 500.0 for the three cases. The 
production of thrombin takes into account reactions with the anticoagulant, so it is 
expected that the areas of higher thrombin concentration correlate with the regions of low 
heparin concentration, which is what is observed. The shapes of the contours are very 
similar for the three cases of bare metal stent, flow-delivered AT:H, and DES-delivered 
AT:H. The flow-delivered heparin case varies very slightly from the other two cases in 
that the thrombin concentration between the stent structures decreases more sharply from 
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the base of the first strut’s trailing edge to the top of the second strut. In all cases the 
concentrations are higher further downstream, which is because some of the thrombin 
and coagulation cascade intermediates from upstream are carried downstream by the 
flow. However, the concentration magnitudes are largely different. The peak 
concentrations of thrombin are roughly 26, 4.8, and 0.26 from the contour figures. 
Figure 21 is a plot of total thrombin concentration in the domain, and shows the 
difference in concentration between the three cases. Both the flow-delivered AT:H and 
DES-delivered AT:H cases demonstrate significant reduction in thrombin production, but 










Figure 22: Mobile, activated platelet contours for (a) bare metal stent, (b) flow-
delivered AT:H, and (c) DES-delivered AT:H at time 0.500=t  for steady flow. The 




Figure 23: Plot of total mobile, activated platelet number density in the domain 











Figure 24: Bound platelet contours for (a) bare metal stent, (b) flow-delivered 
AT:H, and (c) DES-delivered AT:H at time 0.500=t  for steady flow. The insets are 






Figure 25: (a) Plot of total bound platelet number density in the domain over time 
for bare metal stent, flow-delivered AT:H, and DES-delivered AT:H for steady flow. (b) 
The same plot zoomed in on the late time region. 
The mobile, activated platelet contours in figure 22 show similar trends as the 
thrombin. In all cases the activated platelet number density is highest in the recirculation 
zones between stent struts, with greater concentrations further downstream. The 
concentration magnitudes are again very different between the three cases. The total 
mobile, activated platelet number densities are shown in figure 23, and these also follow 
the same trend as the thrombin concentrations in figure 21. The DES-delivered 
anticoagulant is more effective in reducing the amount of platelet activation. 
Figure 24 shows bound platelet contours, which includes platelets that have either 
adhered to the endothelium wall or to other bound platelets. While these contours look 
almost identical between the three cases, the plots of total number densities in figure 25 
do show a small difference from anticoagulant delivery. While the effect is much less 
pronounced, the anticoagulant does decrease bound platelet number density, with the 
drug-eluting stent being more effective than the AT:H delivered through the flow. The 
reason this effect is less pronounced is because in this model bound platelet species can 
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only be produced in close proximity to the wall through adhesion and aggregation 
processes. This condition severely limits the amount of available activated platelets that 
can be converted to bound platelets, so the concentration of bound platelets grows much 
more slowly than that of activated platelets. 
 
3.2.2 Pulsatile Flow 
 
Figure 26: Tissue factor contours at time 0.500=t  for pulsatile flow. The inset is 
zoomed on the region between struts 5 and 6, and includes streamlines for comparison. 
 
 




The pulsatile flow results in general show the same trends as those for steady 
flow. Figure 26 shows the tissue factor contours at time 500.0, which look very similar to 
those seen in figure 17 for steady flow. Figure 27 plots the total tissue factor 
concentration in the domain over time. It is similar to figure 16 for steady flow, but the 
concentration has minor fluctuations due to advection being driven by a pulsatile flow 






Figure 28: AT:H contours for (a) flow-delivered AT:H, and (b) drug-eluting 
stent-delivered AT:H at time 0.500=t  for pulsatile flow. The insets are zoomed on the 





Figure 29: Plot of total AT:H concentration in the domain over time for pulsatile 
flow. 
Figure 28 shows the AT:H complex contours at time 500.0 for both flow-
delivered and DES-delivered anticoagulant. Figure 29 shows the total concentration of 
AT:H in the domain for the pulsatile flow. These figures in general show the same results 
as the steady flow, and the effect of pulsatility on heparin concentration appears to be a 
minor fluctuation that is added to the dominating heparin concentration trends seen in the 
steady case. The drug-eluting stent is more effective at delivering anticoagulant into the 










Figure 30: Thrombin contours for (a) bare metal stent, (b) flow-delivered AT:H, 
and (c) DES-delivered AT:H at time 0.500=t  for pulsatile flow. The insets are zoomed 
on the region between struts 5 and 6, and include streamlines for comparison. 
 
Figure 31: Plot of total thrombin concentration over time in the domain for bare 










Figure 32: Mobile, activated platelet contours for (a) bare metal stent, (b) flow-
delivered AT:H, and (c) DES-delivered AT:H at time 0.500=t  for pulsatile flow. The 






Figure 33: Plot of total mobile, activated platelet number density in the domain 











Figure 34: Bound platelet contours for (a) bare metal stent, (b) flow-delivered 
AT:H, and (c) DES-delivered AT:H at time 0.500=t  for pulsatile flow. The insets are 




Figure 35: (a) Plot of total bound platelet number density in the domain over time 
for bare metal stent, flow-delivered AT:H, and DES-delivered AT:H for pulsatile flow. 
(b) The same plot zoomed in on the late time region. 
Figure 30, figure 32, and figure 34 show the contours of thrombin, mobile 
activated platelets, and bound platelets respectively throughout the domain at time 500.0. 
The plots of concentration over time of these species are shown in figure 31, figure 33, 
and figure 35. In general the same trends are observed that were present for steady input 
flow. The anticoagulant is very effective in reducing the concentrations of thrombin and 
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mobile, activated platelets, with the drug-eluting stent having a significantly larger effect. 
The bound platelet plots demonstrate the same trend, but with a much smaller difference 







This study presents an investigation of stent thrombosis using computational fluid 
dynamics with coupled scalar transport modeling. The flow properties inside a stented 
channel were simulated for a curved, complex geometry, and chemical species transport 
and reaction in the coagulation cascade and platelet interactions were also modeled 
successfully. The two-dimensional simulation was able to deal with both steady input 
flows and pulsatile flows such as those in actual blood flow. Overall, the study 
demonstrated that the chosen methods of numerical modeling are effective in handling 
the problem of stent thrombosis. 
The results of the study showed that antithrombin-heparin complex was an 
effective anticoagulant for a stented channel after angioplasty. For both steady and 
pulsatile parabolic inflow, the delivery of heparin significantly reduced the production of 
thrombin and activation of platelets. The results also showed the effectiveness of drug-
eluting stents as a delivery mechanism for anticoagulant AT:H. In all cases, the drug-
eluting stent outperformed the flow-delivered anticoagulant as a means of reducing the 
concentration of thrombin, activated platelets, and bound platelets, which are all highly 
related to the formation of a blood clot. Furthermore, the amount of anticoagulant 
released into the domain was orders of magnitude smaller for the drug-eluting stents, and 
more AT:H remained localized to the area of injury instead of being convected 
downstream. As the unwanted effects of anticoagulants include bleeding disorders and 
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other medical complications, the benefit of using a lower dose of anticoagulant and 
having it remain in the region of interest is substantial. 
 
5 Future Work 
This report represents a preliminary investigation and as such there are various 
limitations on the scope of this work. The model was entirely two-dimensional and did 
not reflect real blood vessel or stent shapes. An extension to three dimensions with proper 
geometry for the wires of the stent could yield different flow properties and chemical 
transport results. The lengths of the inflow and outflow regions may have an impact on 
the results, which was not tested thoroughly in this study. Also, the input flow used was a 
periodic parabolic profile. However, real blood flow in the coronary artery is closer to a 
Womersley profile created by a fluctuating pressure drop through the artery. Future 
efforts could implement either a Womersley profile or a fluctuating pressure drop as the 
boundary conditions at the inflow and outflow. The expression of tissue factor on the 
injured wall was also greatly simplified in this study. Additionally, the formation of a 
thrombus requires interactions between activated platelets and fibrin, which was not 
modeled here. Also each species was assumed to be advected by the flow without 
affecting it, i.e. massless particles. Accounting for particle masses and their interactions 
with the flow could lead to differences in the flow properties and transport of chemical 
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